Matching Phages to Patients: The Clinical Microbiology Laboratory in Phage Therapy
Year: 2026
Type: article
Abstract: Bacteriophage therapy is increasingly used on a compassionate or magistral basis for infections caused by multidrug-resistant bacteria, particularly carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Phage preparations are usually selected for the individual patient, and that selection depends on testing candidate phages against the patient’s own isolate, which places the clinical microbiology laboratory within the treatment pathway. The laboratory’s role, however, remains poorly defined: phage susceptibility testing lacks standardised methods, validated interpretive criteria, and external quality assessment, and results from spot assays, efficiency of plating, liquid culture kinetics, and automated platforms are not interchangeable. This narrative review describes the laboratory steps of phage therapy, from isolate selection and characterisation to susceptibility testing, monitoring for phage resistance during treatment, and assessment of phage–antibiotic interactions. The available methods are compared by the biological question each addresses, its readout, throughput, sources of variability, and limits of clinical interpretation. The review then sets out what laboratory participation requires in practice—biosafety, quality assurance, documentation and turnaround—and what those requirements imply for settings with endemic carbapenem resistance such as Greece. The testing strategy described is a proposed laboratory framework, not a clinically validated diagnostic algorithm.
Source: Acta Microbiologica Hellenica
DOI: 10.3390/amh71040049
Authors: Rafail Fokas, Apostolos Vantarakis
Institution: University of Patras
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,448
OpenAlex ID: W7236350656
